MET pathway activation has been frequently reported as a mechanism of tumor recurrence in NSCLC (EGFRT790M) treated with erlotinib [23, 29], in melanoma (BRAFV600E) treated with vemurafenib [24], and in GBM treated with bevazicumab [30]. Here, MET is linked to neoplasm.